Besides its limitations, our work clearly demonstrates that the application of FTis can potentiate antitumoral effects of novel KRAS G12C inhibitors and suggests that combination of farnesyl-transferase and KRAS-G12C inhibitors should be explored in the clinical setting both in KRAS-G12C mutant lung adenocarcinoma and in other KRAS-G12C mutant tumors. Here, KRAS is linked to lung adenocarcinoma.